In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the management of RAS mutations. Specifically, in pancreatic ductal adenocarcinoma (PDAC) and the promising results from a Phase 1 study on RMC-6236, a novel multi-selective RAS inhibitor. Here’s a comprehensive look at the discussion and the … Continue reading Is RMC-6236 the real deal or just hype? ASCO GI – Ignacio Garrido-Laguna, MD